Youll receive guidance, accountability, and motivation to continue making progress
Bottom line Wegovy (semaglutide) is a GLP-1 medication that is FDA-approved for individuals living with obesity or overweight
Clinicians must, therefore, extrapolate from established principles for GLP-1 switching namely, avoiding direct dose equivalence and prioritising patient safety as per individual drug summary of product characteristics
Patients should be instructed to seek immediate medical attention for severe abdominal pain (potential pancreatitis), jaundice or right upper quadrant pain (gallbladder disease), decreased urine output (kidney injury), or vision changes
How Do Patients Experience This in Real Life
View options here: GLP-1 Pricing 6